[
  {
    "ts": null,
    "headline": "A Look at Pharma ETFs After Strong Q1 Earnings",
    "summary": "Many pharma bigwigs reported solid results, with some beating on earnings or revenues or both.",
    "url": "https://finnhub.io/api/news?id=268af555da3b9bc4ff0a37ee029804289b139cc81c8494abb1cab238bec319ce",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746719400,
      "headline": "A Look at Pharma ETFs After Strong Q1 Earnings",
      "id": 134335780,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Many pharma bigwigs reported solid results, with some beating on earnings or revenues or both.",
      "url": "https://finnhub.io/api/news?id=268af555da3b9bc4ff0a37ee029804289b139cc81c8494abb1cab238bec319ce"
    }
  },
  {
    "ts": null,
    "headline": "Hartford Equity Income Fund Q1 2025 Commentary",
    "summary": "Hartford Equity Income Fund (I Share) outperformed the Russell 1000 Value Index during the quarter. Read more here.",
    "url": "https://finnhub.io/api/news?id=dfc18cc6bba6eb4df2059eae68ccfdf672f2feb49bdf0816ed5c20a4d712173b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746716700,
      "headline": "Hartford Equity Income Fund Q1 2025 Commentary",
      "id": 134329054,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2187991365/image_2187991365.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Hartford Equity Income Fund (I Share) outperformed the Russell 1000 Value Index during the quarter. Read more here.",
      "url": "https://finnhub.io/api/news?id=dfc18cc6bba6eb4df2059eae68ccfdf672f2feb49bdf0816ed5c20a4d712173b"
    }
  },
  {
    "ts": null,
    "headline": "Can Pfizer (PFE) Climb 25.14% to Reach the Level Wall Street Analysts Expect?",
    "summary": "The mean of analysts' price targets for Pfizer (PFE) points to a 25.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.",
    "url": "https://finnhub.io/api/news?id=d8ea98ab40a66229edee212b8034c5002622142fc6f603229f555c3437cfdd39",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746712508,
      "headline": "Can Pfizer (PFE) Climb 25.14% to Reach the Level Wall Street Analysts Expect?",
      "id": 134325366,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The mean of analysts' price targets for Pfizer (PFE) points to a 25.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.",
      "url": "https://finnhub.io/api/news?id=d8ea98ab40a66229edee212b8034c5002622142fc6f603229f555c3437cfdd39"
    }
  },
  {
    "ts": null,
    "headline": "Want $3,100 in Annual Dividends? Invest $18,000 in Each of These 3 Stocks",
    "summary": "If you invested $54,000 into stocks averaging that kind of a yield, you'd collect just $756 in annual dividend income.  The best part is that you're not taking on significant risk with these investments, either.  Realty Income (NYSE: O), Pfizer (NYSE: PFE), and Target (NYSE: TGT) are all blue chip stocks that you can hang on for the long haul.",
    "url": "https://finnhub.io/api/news?id=1d1e8e4fe17564a4e87db451eb9358d15b4adaeffe2c6c84ec161b94ee19abe0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746697500,
      "headline": "Want $3,100 in Annual Dividends? Invest $18,000 in Each of These 3 Stocks",
      "id": 134325367,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "If you invested $54,000 into stocks averaging that kind of a yield, you'd collect just $756 in annual dividend income.  The best part is that you're not taking on significant risk with these investments, either.  Realty Income (NYSE: O), Pfizer (NYSE: PFE), and Target (NYSE: TGT) are all blue chip stocks that you can hang on for the long haul.",
      "url": "https://finnhub.io/api/news?id=1d1e8e4fe17564a4e87db451eb9358d15b4adaeffe2c6c84ec161b94ee19abe0"
    }
  },
  {
    "ts": null,
    "headline": "Dividend Harvesting Portfolio Week 218: $21,800 Allocated, $2,195.04 In Projected Dividends",
    "summary": "The Dividend Harvesting Portfolio gained 1.98% this week, with a total return of 23.42%. Find out how the portfolio is well-positioned for future rate cuts.",
    "url": "https://finnhub.io/api/news?id=4faff990eac28a45a4081f9ca395cf59998d0baf257e2c3561eac2ef1e345ce7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746694800,
      "headline": "Dividend Harvesting Portfolio Week 218: $21,800 Allocated, $2,195.04 In Projected Dividends",
      "id": 134323355,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1445810162/image_1445810162.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "The Dividend Harvesting Portfolio gained 1.98% this week, with a total return of 23.42%. Find out how the portfolio is well-positioned for future rate cuts.",
      "url": "https://finnhub.io/api/news?id=4faff990eac28a45a4081f9ca395cf59998d0baf257e2c3561eac2ef1e345ce7"
    }
  },
  {
    "ts": null,
    "headline": "Alnylam keeps pushing the rare disease paradigm as RNAi promises even wider indications",
    "summary": "With another rare disease approval under its belt, Alnylam is still revving up the R&D engines for new indications.",
    "url": "https://finnhub.io/api/news?id=05554b25d20119edb6f2950e6c51d9c51944aac5a67b5ea3bea683c57b400d12",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746691200,
      "headline": "Alnylam keeps pushing the rare disease paradigm as RNAi promises even wider indications",
      "id": 134325368,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "With another rare disease approval under its belt, Alnylam is still revving up the R&D engines for new indications.",
      "url": "https://finnhub.io/api/news?id=05554b25d20119edb6f2950e6c51d9c51944aac5a67b5ea3bea683c57b400d12"
    }
  },
  {
    "ts": null,
    "headline": "March/April Readers Tagged 7 Ideal Dividend Dogs From 12 'Safer' Of 36",
    "summary": "Discover the top 10 ReFa/Ro investments with impressive net gains, dividend yields, and target price upsides.",
    "url": "https://finnhub.io/api/news?id=6ee2df39de1eab82aaef9e29c016f4fdb153ef28dfa2d402d4918b65d411e9cb",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746685228,
      "headline": "March/April Readers Tagged 7 Ideal Dividend Dogs From 12 'Safer' Of 36",
      "id": 134321363,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1162435178/image_1162435178.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Discover the top 10 ReFa/Ro investments with impressive net gains, dividend yields, and target price upsides.",
      "url": "https://finnhub.io/api/news?id=6ee2df39de1eab82aaef9e29c016f4fdb153ef28dfa2d402d4918b65d411e9cb"
    }
  },
  {
    "ts": null,
    "headline": "Valneva SE: Still Undervalued Travel Vaccine Bet With Robust 2025 Guidance",
    "summary": "Valneva SE offers exposure to a robust travel vaccine portfolio that includes Ixiaro, Dukoral, and Ixchiq. Read what justifies INRLF stock a Buy.",
    "url": "https://finnhub.io/api/news?id=d5c621b3183a9df78ede9cab222fea4a15cc48bde39f1956e805521a795c3581",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746664239,
      "headline": "Valneva SE: Still Undervalued Travel Vaccine Bet With Robust 2025 Guidance",
      "id": 134314543,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1305955031/image_1305955031.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Valneva SE offers exposure to a robust travel vaccine portfolio that includes Ixiaro, Dukoral, and Ixchiq. Read what justifies INRLF stock a Buy.",
      "url": "https://finnhub.io/api/news?id=d5c621b3183a9df78ede9cab222fea4a15cc48bde39f1956e805521a795c3581"
    }
  }
]